Navigation Links
Reportlinker Adds Lung Cancer Drug Futures
Date:10/19/2010

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lung Cancer Drug Futures

http://www.reportlinker.com/p0315763/Lung-Cancer-Drug-Futures.html

AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Lung Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.

24/7 web access

Quarterly updated pdf reports

Single cost-effective price

All updates including any new drugs added during your licence period

Related news

Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

Although a plethora of platinum-based chemotherapy combinations may be prescribed for the treatment of non small cell lung cancer (NSCLC)....

....the market is currently driven by chemotherapeutic agents such as taxanes and antimetabolites, and the increasing use of targeted therapies. Some of the newer chemotherapy agents such as Eli Lilly's Gemzar and Alimta have become the standard of care in combination with cisplatin or carboplatin and may be used in addition to or instead of the taxanes Taxotere or Taxol/generic paclitaxel.

The lung cancer market is set for radical change. A number of current first-line therapies will become subject to generic competition in the short term. Although chemotherapy will continue to play a significant if diminishing role, industry attention is firmly on the better-tolerated biologics which are already setting the pace in the market and whose influence will grow over the coming years. In 2007, chemotherapy treatments accounted for 68% of the market but are forecast to account for only 32% by 2014, whereas targeted treatments are forecast to increase from 30% to 60% over the same period.

As researchers begin to understand the processes involved in NSCLC formation, several new targeted therapies have evolved which modulate growth factor pathways. For example, Roche's small-molecule tyrosine kinase inhibitor Tarceva (erlotinib) and its best selling anti-angiogenic VEGF inhibitor Avastin (bevacizumab) are gaining credence in second- and first-line therapy for advanced disease, respectively.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Lung Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...

Track the drug's progress and stay abreast of developments

Understand the drug's novelty and mode of action

Evaluate the strength of the company developing/producing the drug

Review opportunities and challenges with Espicom's unique 5-point competitive assessment

Know the launch timeframe for new products or indications

Be aware of promising mid-stage development candidates

Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates

Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…

Novelty/rationale for mechanism of action

Current status

Proof of concept/clinical data

Development risks

Company expertise

Competition within the market-place

Sales forecast (for key late-stage and launched products)

Competitor ratio analysis score

Clinical trial results

OVER 45 CURRENT DRUGS COVERED:

Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved

Bevacizumab

Docetaxel

Erlotinib

Gefitinib

Gemcitabine

Pemetrexed disodium

Paclitaxel

Phase III

Aflibercept

Belagenpumatucel-L

BIBF 1120

BIBW 2992

Canfosfamide

Crizotinib

Figitumumab

MAGE-A3

Motesanib diphosphate

Necitumumab

PF-02341066

PF-299804

Sorafenib

Stimuvax

Sunitinib malate

Talactoferrin alpha

Vadimezan

Phase II

Arenegyr

ARQ 197

AT-101

Axitinib

AZD6244

Bavituximab

Bortezomib

CDP501

CDP791

Cediranib

Cixutumumab

Conatumumab

Custirsen sodium

Dulanermin

Enzastaurin

Gimatecan

Ipilimumab

Linifanib

lxabepilone

MGCD265

OGX-011

Pazopanib

PD-3512676

Pertuzumab

PF-3512676

Ramucirumab

Sagopilone

STA-9090

TG4010

Phase I/II

Retaspimycin

Tivozanib

XL184

Phase I

Everolimus

IMO-2055

Naptumomab estafenatox

Suspended or Discontinued

ABT-751

Cetuximab

Mapatumumab

NOV-002

Paclitaxel

poliglumex

Vandetanib

CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years' of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom's Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom's tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom's leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

Table of ContentsOVERVIEW .... 1

PHASE I... 3

CBP501 .. 3

EVEROLIMUS ..... 4

Mode of Action .. 4

Current Status ... 5

Proof of Concept/Clinical Data ... 6

Development Risks .. 8

Company Expertise .. 8

Competition within the Market-place ..... 9

Competitor Ratio Analysis ..10

Forecast ...10

IMO255 15

Mode of Action 15

Current Status .15

Proof of Concept/Clinical Data .15

Company Expertise .15

Clinical Trial Results: .....15

NAPTUMOMAB ESTAFENATOX .... 17

Mode of Action 17

Current Status .17

Proof of Concept/Clinical Data .18

Development Risks .18

Company Expertise .18

Competition within the Market-place ...18

Competitor Ratio Analysis ..19

Forecast ...19

PHASE I/II .. 21

IXABEPILONE .. 21

Mode of Action 21

Current Status .21

Proof of Concept/Clinical Data .22

Development Risks .22

Company Expertise .22

Competition within the Market-place ...23

Competitor Ratio Analysis ..23

Forecast ...23

Clinical Trial Results 24

RETASPIMYCIN ..... 26

Mode of Action 26

Current Status .26

Proof of Concept/Clinical Data .26

Development Risks .26

Company Expertise .27

Competition within the Market-place ...27

Competitor Ratio Analysis ..28

TIVOZANIB 29

Mode of Action 29

Current Status .29

Proof of Concept/Clinical Data .29

Development Risks .30

Company Expertise .30

Competition within the Market-place ...30

Competitor Ratio Analysis ..31

Forecast ...31

XL184 ... 33

Mode of Action 33

Current Status .33

Proof of Concept/Clinical Data .33

Development Risks .34

Company Expertise .34

Competition within the Market-place ...34

Competitor Ratio Analysis ..35

Forecast ...35

PHASE II ..... 37

ARENEGYR . 37

Mode of Action 37

Current Status .37

Proof of Concept/Clinical Data .38

Development Risks .39

Company Expertise .39

Competition within the Market-place ...40

Competitor Ratio Analysis ..41

ARQ197 42

Mode of Action 42

Current Status .42

Proof of Concept/Clinical Data .42

Development Risks .43

Company Expertise .43

Competition within the Market-place ...43

Competitor Ratio Analysis ..44

Clinical Trial Results: .....44

AT-101 . 47

Mode of Action 47

Current Status .47

Proof of Concept ...48

Development Risks .48

Company Expertise .48

Competition within the Market-place ...49

Competitor Ratio Analysis ..49

Forecast ...49

AXITINIB .... 50

Mode of Action 50

Current Status .50

Proof of Concept/Clinical Data .50

Development Risks .51

Company Expertise .51

Competition within the Market-place ...52

Competitor Ratio Analysis ..53

Forecast ...53

BAVITUXIMAB . 56

Mode of Action 56

Current Status .56

Proof of Concept/Clinical Data .56

Development Risks .57

Company Expertise .57

Competition within the Market-place ...57

Competitor Ratio Analysis ..57

BORTEZOMIB ... 58

Mode of Action 58

Current Status .58

Proof of Concept/Clinical Data .59

Development Risks .60

Company Expertise .60

Competition within the Market-place ....60

Data Exclusivity .....61

Patent Expiry ...61

Generic Competition ....61

Competitor Ratio Analysis ..62

Forecast ...62

Clinical Trial Results 63

CDP791 . 67

Clinical Trial Results 67

CEDIRANIB 68

Mode of Action 68

Current Status .68

Proof of Concept/Clinical Data .69

Development Risks .69

Company Expertise .69

Competition within the Market-place ...70

Competitor Ratio Analysis ..70

Forecast ...71

Clinical Trial Results 72

CIXUTUMUMAB ..... 74

Mode of Action 74

Current Status .74

Proof of Concept/Clinical Data .74

Development Risks .75

Company Expertise .75

Competition within the Market-place ...75

Competitor Ratio Analysis ..75

CONATUMUMAB .... 76

Mode of Action 76

Current Status .76

Proof of Concept ...76

Development Risks .76

Company Expertise .76

Competition within the Market-place ...77

Competitor Ratio Analysis ..77

DULANERMIN .. 78

Mode of Action 78

Current Status .78

Proof of Concept ...78

Development Risks .78

Company Expertise .78

Competition within the Market-place ...79

Competitor Ratio Analysis ..79

Clinical Trial Results 79

ENZASTAURIN . 80

Mode of Action 80

Current Status .80

Proof of Concept/Clinical Data .80

Development Risks .81

Company Expertise .81

Competition within the Market-place ...81

Competitor Ratio Analysis ..81

Forecast ...82

GIMATECAN ..... 83

Mode of Action 83

Proof of Concept/Clinical Data .83

IPILIMUMAB .... 84

Mode of Action 84

Current Status .84

Proof of Concept/Clinical Data .85

Development Risks .86

Company Expertise .86

Competition within the Market-place ...86

Competitor Ratio Analysis ....87

Forecast ...87

Clinical Trial Results ..88

LINIFANIB . 92

Mode of Action 92

Current Status .92

Proof of Concept/Clinical Data .92

Development Risks .93

Company Expertise .93

Competition within the Market-place ...93

Competitor Ratio Analysis ..93

MGCD265 ... 94

Mode of Action 94

Current Status .94

Proof of Concept/Clinical Data .94

Development Risks .94

Company Expertise .94

Competition within the Market-place ...95

Competitor Ratio Analysis ....95

Clinical Trial Results ..95

OGX-011 ..... 96

Mode of Action 96

Current Status .96

Proof of Concept/Clinical Data .96

Development Risks .97

Company Expertise .97

Competition within the Market-place ...98

Competitor Ratio Analysis ....98

PAZOPANIB 99

Mode of Action 99

Current Status .99

Proof of Concept/Clinical Data .99

Development Risks .....100

Company Expertise .....100

Competition within the Market-place .101

Data Exclusivity ...101

Patent Expiry .102

Competitor Ratio Analysis 102

Forecast .102

PERTUZUMAB 105

Mode of Action ....105

Current Status .....105

Proof of Concept/Clinical Data .....105

Development Risks .....106

Company Expertise .....106

Competition within the Market-place .106

Competitor Ratio Analysis 107

Forecast .107

PF-3512676 ... 110

Mode of Action ....110

Current Status .....110

Proof of Concept/Clinical Data .....111

Development Risks .....111

Company Expertise .....111

Competition within the Market-place .111

Competitor Ratio Analysis ..112

RAMUCIRUMAB ... 113

Mode of Action ....113

Current Status .....113

Proof of Concept/Clinical Data .....113

Development Risks .....113

Company Expertise .....113

Competition within the Market-place .114

Competitor Ratio Analysis 114

Forecast .114

SAGOPILONE . 116

Mode of Action ....116

Current Status .....116

Proof of Concept/Clinical Data .....116

Company Expertise .....116

Competition within the Market-place .116

Competitor Ratio Analysis 117

STA-9090 . 118

Mode of Action ....118

Current Status .....118

Proof of Concept/Clinical Data .....119

Development Risks .....119

Company Expertise .....120

Competition within the Market-place .120

Competitor Ratio Analysis 120

PHASE III . 121

AFLIBERCEPT 121

Mode of Action ....121

Current Status .....121

Proof of Concept/Clinical Data .....121

Development Risks .....122

Company Expertise .....122

Competition within the Market-place .123

Competitor Ratio Analysis ..124

Forecast .124

Clinical Trial Results 126

BIBF 1120 128

Mode of Action ....128

Current Status .....128

Proof of Concept/Clinical Data .....129

Development Risks .....129

Company Expertise .....129

Competition within the Market-place .130

Competitor Ratio Analysis ..130

Forecast .130

Clinical Trial Results 131

BELAGENPUMATUCEL-L . 133

Mode of Action ....133

Current Status .....133

Proof of Concept .133

Development Risks .....133

Company Expertise .....134

Competition within the Market-place .134

Competitor Ratio Analysis ..134

BIBW 2992 ..... 135

Mode of Action ....135

Current Status .....135

Proof of Concept/Clinical Data .....136

Development Risks .....136

Company Expertise .....136

Competition within the Market-place .137

Competitor Ratio Analysis ..137

Forecast .137

Clinical Trial Results 138

CANFOSFAMIDE .. 140

Mode of Action ....140

Current Status .....140

Proof of Concept/Clinical Data .....140

Development Risks .....141

Company Expertise .....141

Competition within the Market-place .141

Competitor Ratio Analysis ..142

CRIZOTINIB ... 143

Mode of Action ....143

Current Status .....143

Proof of Concept/Clinical Data .....143

Development Risks .....144

Company Expertise .....144

Competition within the Market-place .144

Competitor Ratio Analysis ..145

Forecast .145

FIGITUMUMAB .... 146

Mode of Action ....146

Current Status .....146

Proof of Concept .146

Development Risks .....147

Company Expertise .....147

Competition within the Market-place .147

Competitor Ratio Analysis 148

MAGE-A3 .. 150

Mode of Action ....150

Current Status .....150

Proof of Concept/Clinical Data .....150

Development Risks .....151

Company Expertise .....151

Competition within the Market-place .151

Competitor Ratio Analysis ..152

Clinical Trial Results 152

MOTESANIB DIPHOSPHATE 153

Mode of Action ....153

Current Status .....153

Proof of Concept/Clinical Data .....153

Development Risks .....153

Company Expertise .....154

Competition within the Market-place .154

Competitor Ratio Analysis 155

Forecast .155

NECITUMUMAB ... 158

Mode of Action ....158

Current Status .....158

Proof of Concept/Clinical Data .....158

Development Risks .....158

Company Expertise .....158

Competition within the Market-place .159

Competitor Ratio Analysis ..160

PF-299804 ..... 161

Mode of Action ....161

Current Status .....161

Proof of Concept/Clinical Data .....161

SORAFENIB .... 162

Mode of Action ....162

Current Status .....162

Proof of Concept/Clinical Data .....164

Development Risks .....164

Company Expertise .....165

Competition within the Market-place .165

Data Exclusivity ...166

Patent Expiry .166

Competitor Ratio Analysis 167

Forecast .167

LAUNCHED PRODUCTS 170

BEVACIZUMAB ..... 170

Mode of Action ....170

Current Status .....170

Proof of Concept/Clinical Data .....173

Development Risks .....176

Company Expertise .....177

Competition within the Market-place .178

Competitor Ratio Analysis 179

Forecast .180

DOCETAXEL .... 187

Mode of Action ....187

Current Status .....187

Proof of Concept .190

Development Risks .....195

Company Expertise .....196

Competition within the Market-place .196

Competitor Ratio Analysis 197

Forecast .198

ERLOTINIB ..... 201

Mode of Action ....201

Current Status .....201

Proof of Concept/Clinical Data .....202

Development Risks .....203

Company Expertise .....204

Competition within the Market-place .204

Data Exclusivity ...205

Patent Expiry .205

Generic Competition ....205

Clinical Trial Results 206

GEFITINIB..... 208

Mode of Action ....208

Current Status .....208

Proof of Concept/Clinical Data .....209

Development Risks .....209

Company Expertise .....209

Competition within the Market-place .210

Competitor Ratio Analysis ..210

Forecast .211

GEMCITABINE ..... 212

Current Status .....212

Proof of Concept/Clinical Data .....213

Development Risks .....214

Company Expertise .....214

Competition within the Market-place .215

Patent Expiry .215

Generic Competition ....215

Competitor Ratio Analysis 217

Forecast .217

Metastatic Breast Cancer .. 218

Pancreatic Cancer. 219

PACLITAXEL ... 221

PEMETREXED DISODIUM .... 222

Mode of Action ....222

Current Status .....222

Proof of Concept/Clinical Data .....223

Development Risks .....223

Company Expertise .....224

Competition within the Market-place .224

Data Exclusivity ...224

Patent Expiry .225

Generic Competition ....225

Competitor Ratio Analysis 225

Forecast .225

Advanced and Metastatic Hepatoma ... 226

Metastatic Breast Cancer .. 226

SUSPENDED .... 228

MAPATUMUMAB .. 228

Mode of Action ....228

Current Status .....229

Proof of Concept .229

Development Risks .....229

Company Expertise .....230

Competition within the Market-place .230

Competitor Ratio Analysis ..230

Forecast .230

Clinical Trial Results 230

WITHDRAWN/DISCONTINUED ..... 232

ABT-751 .... 232

Mode of Action ....232

Current Status .....232

NOV-002 ... 233

Mode of Action ....233

Current Status .....233

Proof of Concept .233

Development Risks .....234

Company Expertise .....234

Competition within the Market-place .234

Competitor Ratio Analysis 235

Forecast .235

METHODOLOGY ... 236

To order this report:Biotechnology Industry: Lung Cancer Drug Futures

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Prostate Cancer Drug Futures
2. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
3. Reportlinker Adds Deep Analysis Report on Chinas Disinfectant Market 2010-2015
4. Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures
5. Reportlinker Adds The Top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends
6. Reportlinker Adds Global Minimally Invasive Surgery Market.(2010 - 2015)
7. Reportlinker Adds Global Diagnostic ECG Market (2010 - 2015)
8. Reportlinker Adds Global Wound Care Products Industry
9. Reportlinker Adds Global Veterinary Vaccines Industry
10. Reportlinker Adds Global Urological Catheters Industry
11. Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories (das "Unternehmen"), ein Weltführer bei schnellen Tests für ... einer Version mit geringeren Kosten einzuführen.  Continue ... ... INSTI Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444833 ) Der von ...
(Date:12/2/2016)... , December 2, 2016 ... its past losses following Trump,s victory early in November. ... and fund managers are now predicting an uptick in ... four equities to see how they have fared at ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: FOLD ...
(Date:11/30/2016)... DUBLIN , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring ... ... The full report suite on ... cerebrospinal fluid external drainage systems, intracranial pressure monitoring devices, detachable ...
Breaking Medicine Technology:
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... to announce that we have been designated as a Cigna Infertility Center of ... exceed rigorous performance standards. , “It’s an honor to be designated a ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my toothbrush ... N.J. "I thought that there had to be a way to prevent this mess, ... to prevent saliva and toothpaste from running down the brush handle onto the hand ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For Discovery, a ... opening of a new eating disorder treatment center location in Palm Beach Gardens, ... and adolescents, both males and females ages 10 and older with eating disorders, ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... workers have been a focus of public policymakers and system stakeholders in many ... (WCRI) released its Medical Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
Breaking Medicine News(10 mins):